(Sharecast News) - Eli Lilly said on Thursday that it has agreed to buy AtaiBeckley, a clinical-stage biopharmaceutical company developing therapeutics for mental health conditions, for $2.8bn.
AtaiBeckley's lead asset, BPL-003 (mebufotenin benzoate), is a synthetic form of 5-MeO-DMT administered intranasally for treatment-resistant depression, which affects millions of people in the...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE